Leveraging mitochondrial-programmed cell death dynamics to enhance prognostic accuracy and immunotherapy efficacy in lung adenocarcinoma
The MPCDS provides personalized risk assessment and immunotherapy interventions for individual LUAD patients. NME4, a key gene within the MPCDS, has been identified as a novel oncogene associated with immune exclusion and may serve as a new target for LUAD intervention and immunotherapy.
Authors
- Zhenfa Zhang (ORCID: https://orcid.org/0000-0002-9627-2590)
- Guangyao Zhou (ORCID: https://orcid.org/0000-0002-8966-4617)
- Yanan Cui (ORCID: https://orcid.org/0000-0003-3579-0690)
- Lianmin Zhang (ORCID: https://orcid.org/0000-0002-7419-9628)
Institutions
- Tongji University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Shanghai Pulmonary Hospital (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/jitc-2024-010008
- Citations
- 64
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 18.08
Funders
- Natural Science Foundation of Tianjin City